All In Biotech

Drug Trial Radar · NCT03053869

Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free)

Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free): A Two-centre Pilot Study to Determine the Feasibility of a Multi-centre, Randomized, Cluster Crossover Trial

Last checked: Nov 19, 2026Latest source record: Oct 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

480

Actual

Start

Apr 1, 2017

Primary completion

Sep 30, 2018

Study completion Sep 30, 2018

Sponsor

Lead sponsor
McMaster UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hamilton Health Sciences Corporation
First posted
Feb 15, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this two-centre pilot research study is to establish the feasibility of conducting a full trial that seeks to determine if a cardiac anesthesia policy that uses alternatives to benzodiazepine medications is better at preventing delirium after cardiac surgery when compared with a cardiac anesthesia policy that uses benzodiazepine medications.

Conditions

  • Post-operative Delirium

Interventions

  • Benzodiazepine - limited use strategyDrug

    1. No routine use of any intraoperative benzodiazepines. 2. Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence. 3. Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia.

  • Benzodiazepine - Ad libitum strategyDrug

    1. Administration of some benzodiazepine to most patients undergoing cardiac surgery. 2. Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confusion Assessment Method (CAM) assessmentTime frame: 1 day
  2. Completion of a minimum of at least 1 CAM assessment per dayTime frame: 1 day
  3. Protocol adherenceTime frame: 4-week crossover period

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • St. Boniface Hospital

    Winnipeg, Manitoba, Canada

  • Dr Summer Syed

    Hamilton, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.